Novel myosin-based therapies for congenital cardiac and skeletal myopathies.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27412953.
- Also identified by DOI 10.1136/jmedgenet-2016-103881 and PMC identifier 5099184.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The dysfunction in a number of inherited cardiac and skeletal myopathies is primarily due to an altered ability of myofilaments to generate force and motion. Despite this crucial knowledge, there are, currently, no effective therapeutic interventions for these diseases. In this short review, we discuss recent findings giving strong evidence that genetically or pharmacologically modulating one of the myofilament proteins, myosin, could alleviate the muscle pathology. This should constitute a research and clinical priority.
Medical subject headings
- Cardiomyopathies
- Muscular Diseases
- Myosins